Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
80 hedge funds and large institutions have $227M invested in Concert Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 17 reducing their positions, and 9 closing their positions.
963% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $105K
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
94% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 17
79% more capital invested
Capital invested by funds: $127M → $227M (+$100M)
14% more funds holding
Funds holding: 70 → 80 (+10)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.08M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$4.08M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.21M |
| 5 |
BlackRock
New York
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.5M |
| 2 |
Renaissance Technologies
New York
|
-$1.73M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$934K |
| 5 |
Walleye Capital
New York
|
-$840K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
76
Steward Partners Investment Advisory
New York
| $13K | – | – | – |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | +$5.11K | +843 | +2,108% |
|
78
Wells Fargo
San Francisco,
California
| $2K | +$661 | +109 | +62% |
|
|
DBG
79
De Burlo Group
Boston,
Massachusetts
| $1.34K | +$1.21K | +200 | New |
|
|
AWM
80
AllSquare Wealth Management
Albany,
New York
| $1K | – | – | – |
|
|
81
Walleye Capital
New York
| – | -$840K | -199,500 | Closed |
|
82
Marshall Wace
London,
United Kingdom
| – | -$374K | -89,146 | Closed |
|
|
VF
83
Virtu Financial
New York
| – | -$275K | -65,416 | Closed |
|
|
PVI
84
Pura Vida Investments
New York
| – | -$187K | -44,357 | Closed |
|
|
XT
85
XTX Topco
George Town,
Cayman Islands
| – | -$125K | -29,766 | Closed |
|
86
D.E. Shaw & Co
New York
| – | -$109K | -25,901 | Closed |
|
|
CCM
87
CAAS Capital Management
New York
| – | -$49K | -11,534 | Closed |
|
88
Squarepoint
New York
| – | -$47K | -11,265 | Closed |
|
89
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$6K | -1,394 | Closed |
|
CNCE Hedge Fund Activity: Q3 2022 in Review
80 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2022, worth a combined $227M — up 79% from $127M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CNCE positions and 9 closed out — a net gain of 10 holders — while 33 added to existing stakes and 17 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $6.08M. The largest seller was RA Capital Management, cutting an estimated $13.5M.
- 80 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2022, up from 70 in Q2 2022.
- Funds reported $227M of Concert Pharmaceuticals, Inc. stock for Q3 2022, up 79% quarter-over-quarter.
- 19 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2022 and 9 closed out, a net change of +10 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2022 was Tang Capital Management, an estimated $6.08M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2022 was RA Capital Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2022.